Table 1.

Baseline patient demographics and disease characteristics (ITT analysis sets)

Low/Negative EGFRHigh EGFR
<1% EGFR (n = 81)1- 9% EGFR (n = 111)All patients* (N = 203)≥10% EGFR (N = 185)
Sex, males (%)46 (56)63 (57)114 (56)100 (54)
Race/ethnicity, n (%)
    White/Caucasian59 (73)84 (76)151 (74)144 (78)
    Black/African American15 (19)17 (15)34 (17)15 (8)
    Hispanic/Latino3 (4)9 (8)13 (6)19 (10)
    Other4 (5)1 (1)5 (2)7 (4)
Mean age in y (minimum, maximum)60 (20, 85)62 (35, 84)61 (20, 85)60 (27, 82)
Primary tumor type, n (%)
    Colon cancer52 (64)84 (76)145 (71)143 (77)
    Rectal cancer29 (36)26 (23)57 (28)42 (23)
Time since primary diagnosis, median mo (minimum, maximum)27.0 (10, 84)29.4 (7, 138)28.0 (7, 138)25.5 (7, 176)
Time since metastatic disease diagnosis, median mo (minimum, maximum)21.1 (7, 59)22.1 (7, 75)21.9 (7, 75)20.6 (6, 83)
ECOG status, n (%)
    039 (48)58 (52)102 (50)61 (33)
    137 (46)44 (40)87 (43)103 (56)
    25 (6)8 (7)13 (6)20 (11)
    30001 (1)
Patients with EGFR tumor staining, n (%)
    <1%81 (100)081 (42)1 (1)
    1-9%0111 (100)111 (57)9 (5)
    10-20%002 (1)116 (63)
    21-35%001 (1)20 (11)
    >35%00039 (21)
Tumor cells with EGFR tumor staining, mean % (SD)01.9 (1.7)1.3 (2.7)24.6 (20.4)
Highest staining intensity, n (%)
    3+ (strong)03 (3)3 (2)32 (17)
    2+ (moderate)011 (10)11 (6)87 (47)
    1+ (weak)1 (1)97 (87)101 (52)65 (35)
    0 (negative)80 (99)080 (41)1 (1)
Tumor cells with highest staining intensity, mean % (SD)01.8 (1.5)1.3 (2.7)12.2 (11.2)
  • *Includes patients without available EGFR status.

  • Date of enrollment minus date of diagnosis.